If placebo already moves HAM-D, why swallow a capsule that takes weeks?
Write the Friday-lift claim first
Someone will tell you the capsule 'kicked in' after two good nights. Write that down. Then open section 14.
The prescribing information is blunt about timing. As with other drugs for major depression, the full effect may be delayed. For obsessive-compulsive disorder the same label says the full therapeutic effect may wait until five weeks or longer. That is not a counseling slogan invented on this desk. It is how the trials were built. Five- and six-week depression studies. Thirteen-week OCD studies. If your review clock is a weekend, you are scoring a different object than the FDA scored.
Placebo response in depression is large. A meaningful share of people improve on a dummy pill, so the extra gain on fluoxetine is real and also smaller than raw 'it helped me' stories imply. Strike two false exits at once: 'it does nothing' and 'it should have fixed Friday.' The honest middle is incremental, slow, and worth the wait where the indication is strong. Mechanism and half-life that explain the lag sit in the Prozac 20 mg fact line.
HAM-D in the adult depression rooms
Adult efficacy was studied in five- and six-week placebo-controlled trials of depressed outpatients whose diagnoses mapped to major depressive disorder. Fluoxetine beat placebo on the Hamilton Depression Rating Scale. It also beat placebo on HAM-D pieces the label bothers to name: depressed mood, sleep disturbance, and the anxiety subfactor. Those are scale points, not vibes. They are also short rooms. Six weeks is long if you are the patient. It is brief if you expected a personality rewrite.
Response in later analyses often means a 50 percent drop on HAM-D. Remission is tighter - the elderly 20 mg pair used a total endpoint HAM-D of 8 or less. Averages hide people who move a lot and people who barely move. A first SSRI helping a good fraction, doing little for others, and sometimes needing a switch is the ordinary pattern, not a Prozac-specific failure. Comparability with older antidepressants, not superiority, is the accurate adult read.
Twenty milligrams in the over-60 studies
Two six-week controlled studies randomized 671 older outpatients to Prozac 20 mg or placebo.
Those rooms matter because this site's SERP lock is 20 mg, and the label still treats 20 mg daily as enough for many adults with major depression. In patients 60 and older, 20 mg produced a higher rate of response and of remission than placebo. Discontinuations for adverse reactions were 12 percent on drug and 9 percent on placebo - close enough that 'the elderly cannot tolerate it' does not survive the table.
Do not inflate that into '20 mg is the only dose anyone needs.' The adult depression range on the label runs 20 to 80 mg. The point of the elderly pair is narrower: the same capsule strength this file keeps naming already had randomized backing in a group people often assume needs a special start. If someone is shopping 'Prozac 20 mg reviews' and wants a number instead of a vibe, this is one of the cleaner numbers the label still prints.
CDRS-R in children, not a grown-up scale
Pediatric depression used a different yardstick. Two eight- to nine-week placebo-controlled trials randomized 315 outpatients - 170 children aged 8 to under 13, 145 adolescents 13 to 18 - on 20 mg daily. Fluoxetine beat placebo on the Childhood Depression Rating Scale-Revised total score in each study on its own. Subgroup cuts did not scream a sex or age split on that scale.
Approval in pediatric major depression starts at age 8. That is a short list among antidepressants, and it is why this molecule still appears in rooms where many siblings do not. It is also why the boxed suicidality language and the trial benefit have to sit in the same sentence. Benefit on CDRS-R does not cancel the need to watch mood and behavior in the first weeks. The watch plan belongs on the safety card. The score belongs here.
Relapse after the open-label stretch
Acute rooms answer 'did the scale move.' Maintenance rooms answer 'did the gain hold.' One study took outpatients who had responded after 12 open weeks on 20 mg - modified HAMD-17 of 7 or less for the last three weeks, no longer meeting major-depression criteria - then randomized 298 of them to stay on 20 mg or switch to placebo. At 38 weeks of double-blind time (50 weeks total), relapse was lower on fluoxetine. Relapse meant two weeks of meeting the diagnosis again, or a modified HAMD-17 of 14 or more for three weeks.
A second maintenance design responded people for three straight weeks after 13 open weeks on 20 mg, then randomized them to daily 20 mg, a 90 mg once-weekly delayed-release capsule, or placebo. Daily 20 mg held a longer time to relapse than placebo across 25 weeks. File that as evidence that staying on the dose that worked beats stopping because you feel fine in month three. It is not a command to stay forever. Duration is a clinical decision. The relapse curves are why 'I feel well, so the trial is over' is a weak review.
Two OCD studies, one messy dose curve
OCD is where reviewers who only read depression blogs go quiet. The rooms were longer and the milligrams were fixed.
Two 13-week multicenter studies enrolled adults with moderate to severe OCD. Mean baseline Yale-Brown Obsessive Compulsive Scale totals sat between 22 and 26. Patients took fixed morning doses of 20, 40, or 60 mg, or placebo. In Study 1, fluoxetine cut Y-BOCS by about 4 to 6 points against a 1-point placebo drop. In Study 2, the drug cut about 4 to 9 points against the same 1-point placebo drop. Study 1 showed no dose-response. Study 2 did, with the two higher arms looking better on the numbers.
That split is why a responsible review does not shout 'OCD always needs 60.' The label still starts adults at 20 mg in the morning, allows a rise after several weeks, names 20 to 60 mg as the usual range, and notes that open work tolerated up to 80. Underdosing and quitting at week three remain the common fumbles. Cognitive behavioral therapy still does heavy lifting. The drug is first-line pharmacotherapy, not a solo cure, and the wait is often longer than the depression wait. Practical titration lives on the weeks-and-taper card.
CGI percentages and the pediatric CY-BOCS arm
| CGI (pooled OCD completers) | Placebo | 20 mg | 40 mg | 60 mg |
|---|---|---|---|---|
| Much or very much improved | 11% | 36% | 39% | 47% |
| No change | 64% | 41% | 33% | 29% |
| Worse | 8% | 0% | 0% | 0% |
Pooled completers from the two adult OCD studies, scored on Clinical Global Impression improvement, are the cleanest 'review' table the label prints. Much improved or very much improved: 11 percent on placebo, 36 percent on 20 mg, 39 percent on 40 mg, 47 percent on 60 mg. Worse: 8 percent on placebo, zero on every fluoxetine arm. No change still sat at 41 percent even on 20 mg. That is a real drug and a large group who barely moved. Both facts belong in the same paragraph.
The pediatric OCD trial randomized 103 patients - 75 children 7 to under 13, 28 adolescents 13 to under 18 - for 13 weeks. They started at 10 mg for two weeks, 20 mg for two weeks, then 20 to 60 mg by response and tolerability. Fluoxetine beat placebo on the Children's Yale-Brown scale. Approval for OCD in children starts at age 7. If a review pretends pediatric OCD is folklore, strike it. If a review pretends every child on 20 mg is 'much improved,' strike that too.
What the reviews skip on purpose
Bulimia and panic sit on the same label and they are not this page's job. File one line each so nobody thinks the desk hid them. In three bulimia trials, only 60 mg - not 20 mg - beat placebo on binge and vomit counts. Panic starts at 10 mg because early activation can mimic the anxiety the person came in with. Premenstrual dysphoric disorder was sold for a time as Sarafem, same molecule, different paint. Those are real approvals. They are not the HAM-D and Y-BOCS argument this review was hired to have.
Against sertraline or escitalopram, depression efficacy is broadly similar. Fluoxetine's long active metabolite, strong CYP2D6 inhibition, and activating tilt are the fit questions, not a potency crown. A review that crowns a winner from forum stars is not reading section 14. Origin of the 20 mg shelf is in the Lilly long-shot file. The molecule as a single note remains the Prozac 20 mg fact line.
Reader mail
Reader questions on this article
Answered by Dr. Sofia Kessler, MD · Internal medicine & clinical pharmacology
Trial-file questions came in after this review. Answers are teaching lines. They do not know your scale scores.
Because 'placebo moves the scale' is not the same sentence as 'the drug adds nothing.' Depression trials show a large dummy-pill response, so the extra fluoxetine gain is real and modest on average. Averages also hide strong responders. For moderate to severe major depression, and especially for OCD on Y-BOCS, the drug beat placebo across the rooms the label cites. I tell people to be skeptical of Friday testimonials and still take the randomized separation seriously. Ignoring a tool because placebo is powerful would throw away the part the FDA actually scored.
Why do side effects show up on day one when the review says wait five weeks?
Different clocks. Nausea, jitter, and broken sleep follow the immediate serotonin bump. Mood and obsession scores wait on slower adaptations the five- and six-week depression rooms and the thirteen-week OCD rooms were built to catch. You can feel the capsule before you feel the point of the capsule. That mismatch makes people quit in week two, which is right before many of the labeled endpoints were even measured. Early adverse effects often settle in a week or two. Worsening mood, new agitation, or self-harm thoughts are not 'early adjustment' - those go back to the prescriber the same day, especially under 25.
The OCD table shows 36 percent much improved on 20 mg. Is that a good review or a bad one?
It is an honest review. Thirty-six percent much or very much improved on 20 mg versus 11 percent on placebo is a clear separation. Forty-one percent with no change on the same 20 mg arm is also a clear limit. I will not let a marketing sentence eat the second number. Study 2 hinted that 40 and 60 mg looked better; Study 1 did not. That is why the label still starts at 20 mg and allows a climb after several weeks instead of opening every adult at 60. Pair the capsule with exposure-based therapy. Underdosing and a three-week patience window are how OCD treatment gets fumbled.
My friend takes 60 mg for bulimia and I take 20 mg for depression. Who has the wrong dose?
Quite possibly neither of you. Dose follows the indication the trials used, not body size and not a forum average. Depression rooms often used 20 mg and the elderly pair showed 20 mg can be enough. Bulimia rooms tested 20 and 60 mg; only 60 mg beat placebo on binge and vomit counts. OCD sat on fixed 20, 40, and 60 mg for thirteen weeks. Same molecule, different targets. A 60 mg bulimia dose is what the evidence supports, not a prescribing error. Psychological treatment still does a large share of the work in eating-disorder care.
Is a 90 mg weekly capsule the same review as 20 mg daily?
No. The weekly 90 mg delayed-release form showed up in a maintenance design after people had already responded to daily 20 mg. Daily 20 mg beat placebo on time to relapse in that room. Weekly dosing is a continuation trick for people who already responded, not a way to start, and not a way to skip the five-week wait. If a review treats 90 mg weekly as a stronger 'hit,' strike it. The acute depression and OCD evidence this page files is daily dosing scored on HAM-D, CDRS-R, or Y-BOCS.
Do children get the same trial story as adults?
Same molecule, different scales and ages. Pediatric depression used CDRS-R in 8- to 18-year-olds on 20 mg for eight to nine weeks and beat placebo in both studies. Pediatric OCD used CY-BOCS in 7- to 17-year-olds over thirteen weeks after a 10-then-20 mg start. Fluoxetine is among the few antidepressants specifically labeled for pediatric depression (from 8) and pediatric OCD (from 7). That is a genuine evidence edge. It does not erase the boxed suicidality language. Benefit and watch plan have to travel together. I will not sell one without the other.
Should I pick fluoxetine over sertraline because the reviews look older and thicker?
Thicker paper is not a potency crown. For depression the common SSRIs are broadly similar on average. Fluoxetine's long norfluoxetine tail forgives missed doses and eases some exits. It also strongly blocks CYP2D6 and sits on the activating end of the class. Escitalopram barely touches those enzymes. Sertraline sits between. A good prescriber matches the fit - your other medicines, whether you run anxious or flat, whether you miss doses - not a 'best SSRI' listicle. MedlinePlus keeps readable class notes at MedlinePlus.
How will I know the trial-style benefit is happening if I live inside the mood?
Look for unglamorous change: slightly less morning dread, sleep that is less shredded, a task you had dropped getting five minutes of attention. Other people often notice before you do. A rough weekly note beats a feeling in week six compared with week one, because slow improvement is easy to miss from inside. An adequate depression trial is still measured in weeks at a proper dose, longer for OCD. Little movement after that is useful data, not a verdict on you. Switching, adjusting, or adding therapy is ordinary. Do not stop on a solo decision. Plan the next step with the person who wrote the prescription.
Where is the rest of the label if this review only wants HAM-D and Y-BOCS?
On purpose. Origin and the Indianapolis bet are in the Lilly long-shot file. Start, five-week wait, taper, MAOI gap, and the boxed line are on the weeks-and-taper card. The single labeled note is the Prozac 20 mg fact line. Current FDA wording lives at the FDA. None of those pages is your chart. Bring your own scores to a clinician who can see you.
General education from a clinician, not personal medical advice. Bring your own history to your own prescriber.
Last Updated